Gilead Sciences, Inc. (Nasdaq:GILD) and Phenex Pharmaceuticals AG, a
privately-held biotechnology company, today announced the signing of a
definitive agreement under which Gilead will acquire Phenex’s Farnesoid
X Receptor (FXR) program comprising small molecule FXR agonists for the
treatment of liver diseases including nonalcoholic steatohepatitis
(NASH). Under the terms of the agreement, Gilead will pay Phenex an
upfront payment plus additional payments based upon achievement of
certain development milestones that may potentially be worth up to $470
By Justin Baer And Chelsey Dulaney
Morgan Stanley has terminated an employee for allegedly stealing sensitive account information from 350,000 of its wealth-management clients, or about 10% of the firm's total, and posting some of the data on the Internet.
MetLife, Inc. (NYSE:MET) today announced that it had completed the
mergers of its subsidiaries MetLife Insurance Company of Connecticut,
MetLife Investors USA Insurance Company, MetLife Investors Insurance
Company and Exeter Reassurance Company Limited.
Intuit Inc. (Nasdaq:INTU) is
launching QuickBooks Online Self-Employed, a new product that makes it
easy for the rapidly expanding population of freelancers and independent
contractors to simplify their financial lives.
Baxter International Inc. (NYSE:BAX) announced the filing of an initial
Form 10 Registration Statement with the U.S. Securities and Exchange
Commission (SEC) in connection with the company’s previously announced
plan to spin off its biopharmaceutical business.
NEW YORK, NY --
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.